Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALTO: S-1 versus capecitabine in first-line treatment of metastatic colorectal cancer
2013-002147-28Phase 3Active
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in metastatic colon cancer (mCRC) comparing S-1 arm with Capecitabine arm (2 arms). Primary endpoint: Incidence of grade 3 hand-foot syndrome. Started Jun 2013; status: active.
02
Drugs
tegafurcapecitabine
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2013-002147-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002147-28.